Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
28,297,751
-
Share change
-
+7,530,146
-
Total reported value
-
$433,552,379
-
Put/Call ratio
-
82%
-
Price per share
-
$15.32
-
Number of holders
-
100
-
Value change
-
+$112,164,880
-
Number of buys
-
76
-
Number of sells
-
26
Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q3 2020
As of 30 Sep 2020 Kiniksa Pharmaceuticals Intern - COM (KNSA) had 100 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 28,297,751 shares of stock of the company.
Largest 10 holders included HILLHOUSE CAPITAL ADVISORS, LTD., BAKER BROS. ADVISORS LP, Consonance Capital Management LP, VANGUARD GROUP INC, AMERIPRISE FINANCIAL INC, BlackRock Inc., ArrowMark Colorado Holdings LLC, Vivo Capital, LLC, JANUS HENDERSON GROUP PLC, and CITADEL ADVISORS LLC.
This table shows 100 institutional shareholders of the security as of 30 Sep 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.